News | February 09, 2009

SNM Workshop Underscores Imaging’s Value in Drug Development

February 9, 2009 - Presenters at the workshop stressed the need for the correct imaging biomarker available to accelerate the completion of clinical trials, as well as imaging standardization, consistent manufacturing practices and regulatory considerations, at The SNM Clinical Trials Network Community Workshop held on Feb. 8, 2009, in Clearwater, FL.
Speakers from the field of molecular imaging, regulatory agencies and pharmaceutical developers focused on the critical need to increase the use of imaging biomarkers in clinical trials and called for immediate action.

"The time to develop new imaging biomarkers is now," said Jeff Evelhoch, vice president of imaging at Merck. "We must come together as a community to make this happen, working together to facilitate the regulatory process."

Experts in oncology, cardiology, dementia and cell therapeutics discussed the important role that imaging biomarkers - indicators of a particular disease state or a particular state of an organism - can play in drug development studies. Other speakers addressed the challenges that researchers and imagers currently face in harmonizing imaging results between different locations in a multicenter trial.

“SNM’s Clinical Trials Network was conceived just for this reason: to create a standardized protocol across multiple sites in the U.S. and internationally in order to expedite the creation of new biomarkers for use in clinical trials,” said Michael Graham, M.D., Ph.D., president-elect of SNM and a chair of SNM’s Clinical Trials Network. “We are currently registering potential imaging sites, assessing their ability to participate in the Clinical Trials Network, and looking forward to announcing the first clinical trial in late 2009.”

“The role of medical imaging in clinical trials is rapidly increasing due to the ability to provide patient assessment and early drug trial results,” said Gustav K. von Schulthess, M.D., Ph.D., professor and director of nuclear medicine, University Hospital, Zurich, Switzerland, who was the keynote speaker at the workshop. “SNM’s Clinical Trials Network is expected to assist greatly by creating and enforcing standards among multiple trial sites, which, in the end, will benefit imagers, pharmaceutical manufacturers and patients.”

Pharmaceutical developer representative Diane Jorkasky, M.D., FACP, and former vice president of Global Clinical Research Operations at Pfizer, helped the audience understand the industry perspective on the use of medical scanning in drug development, how different therapeutic areas view the value of that scanning and how “go/no-go” decisions are used when employing such imaging.

"Only through partnerships comprising researchers, pharmaceutical developers and government will we be able to achieve novel approaches necessary to establishing successful clinical trials," she said. According to Dr. Jorkasky, one of the key attributes of a standardized trials protocol is that imagers and pharmaceutical developers will have insight earlier whether a drug under development shows potential for truly helping patients who can benefit from molecular imaging pharmaceuticals.

Wendy Sanhai, Ph.D., senior scientific advisor, Immediate Office of the Commissioner, U.S. Food and Drug Administration, closed the day's presentations by acknowledging the critical role of medical imaging agents in early diagnosis, as well as patient care and monitoring disease progression. "Medical imaging techniques can provide real-time feedback on drug effectiveness and separate those patients who respond from those who do not and thus allow successful clinical decisions for the most effective treatment," she said.

Dr. Sanhai described clinical studies that incorporate imaging and that are currently underway in collaboration with multiple stakeholders. Her presentation provided updates on studies being facilitated within the Biomarker Consortium--a public-private research partnership of the Foundation for the National Institutes of Health--as well as efforts underway at FDA to facilitate biomarker development.

For more information:

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Overlay Init